CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Abraxis Bioscience, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Abraxis Bioscience, Inc.
11755 Wilshire Blvd.
Suite 2000
Phone: 310-883-1300p:310-883-1300 Los Angeles, CA  90025  United States Fax: 310-998-8553f:310-998-8553
This company ceased filing statements with the SEC on 10/25/2010.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Abraxis BioScience, Inc. is an integrated biotechnology company. It is engaged in the discovery, development and delivery of next-generation therapeutics and technologies that offer patients treatments for cancer and other critical illnesses. Its portfolio includes the protein-based nanoparticle chemotherapeutic compound (Abraxane), which is based on its tumor targeting technology known as the nab technology platform. The Company’s research and development approach is based on the integration of its nab tumor targeting technology, its natural product drug discovery platform, its multi-functional chemistry capabilities with its in-house clinical trial and regulatory strengths, combined with its nanoparticle manufacturing capabilities.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201012/31/2009YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer Bruce J.Wendel 56 10/15/2010 11/1/2007
Senior Vice President - Finance, Principal Accounting and Financial Officer Mitchell K.Fogelman 58 2/3/2010 10/1/2009

Business Names
Business Name
Abraxis Bioscience Australia Pty Ltd.
Abraxis BioScience Canada, Inc.
Abraxis BioScience France SAS
17 additional Business Names available in full report.

General Information
Outstanding Shares: 40,465,643 (As of 7/31/2010)
Shareholders: 68
Stock Exchange: NASD
Federal Tax Id: 300431735
Fax Number: 310-998-8553


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023